| Proteomic research in sarcomas–current status and future opportunities J Burns, CP Wilding, RL Jones, PH Huang Seminars in Cancer Biology 61, 56-70, 2020 | 54 | 2020 |
| Can a silver-coated arthrodesis implant provide a viable alternative to above knee amputation in the unsalvageable, infected total knee arthroplasty? CP Wilding, GA Cooper, AK Freeman, MC Parry, L Jeys The Journal of arthroplasty 31 (11), 2542-2547, 2016 | 43 | 2016 |
| The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib CP Wilding, ML Elms, I Judson, AC Tan, RL Jones, PH Huang Expert Review of Anticancer Therapy 19 (11), 971-991, 2019 | 34 | 2019 |
| The adequacy of tissue microarrays in the assessment of inter-and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma ATJ Lee, W Chew, CP Wilding, N Guljar, MJ Smith, DC Strauss, C Fisher, ... Scientific Reports 9 (1), 14602, 2019 | 28 | 2019 |
| The impact of COVID-19 on trauma and orthopaedic patients requiring surgery during the peak of the pandemic: a retrospective cohort study ND Mackay, CP Wilding, CR Langley, J Young Bone & Joint Open 1 (9), 520-529, 2020 | 22 | 2020 |
| Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? E Cojocaru, C Wilding, B Engelman, P Huang, RL Jones Current Molecular Biology Reports 6, 1-9, 2020 | 22 | 2020 |
| Tackling drug resistance in EGFR exon 20 insertion mutant lung cancer L Pacini, AD Jenks, S Vyse, CP Wilding, A Arthur, PH Huang Pharmacogenomics and personalized medicine, 301-317, 2021 | 19 | 2021 |
| Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma FE Chamberlain, C Wilding, RL Jones, P Huang Expert Opinion on Investigational Drugs 28 (6), 505-511, 2019 | 16 | 2019 |
| Tropomyosin receptor kinase inhibitors in the management of sarcomas CP Wilding, HH Loong, PH Huang, RL Jones Current opinion in oncology 32 (4), 307-313, 2020 | 14 | 2020 |
| Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry M Milighetti, L Krasny, ATJ Lee, G Morani, C Szecsei, Y Chen, N Guljar, ... Journal of Proteomics 241, 104236, 2021 | 13 | 2021 |
| The proteomic landscape of soft tissue sarcomas J Burns, CP Wilding, L Krasny, X Zhu, M Chadha, YB Tam, H Ps, ... Nature Communications 14 (1), 3834, 2023 | 8 | 2023 |
| Which factors affect the ability to kneel following total knee arthroplasty? An outpatient study of 100 postoperative knee replacements CP Wilding, M Snow, L Jeys Journal of Orthopaedic Surgery 27 (3), 2309499019885510, 2019 | 7 | 2019 |
| OrthOncoCon-2014: Continuing education in musculoskeletal oncology A Gulia, C Wilding, M Suman, A Puri Indian Journal of Cancer 52 (2), 184-185, 2015 | 4 | 2015 |
| Proteomic profiling identifies co-regulated expression of splicing factors as a characteristic feature of intravenous leiomyomatosis L Krasny, CP Wilding, E Perkins, A Arthur, N Guljar, AD Jenks, C Fisher, ... Cancers 14 (12), 2907, 2022 | 2 | 2022 |
| Late Infections of the Knee Joint: Two-staged Static Solutions C Wilding, M Parry, L Jeys Periprosthetic Joint Infections Changing Paradigms, 249-265, 2016 | 1 | 2016 |
| Mapping the dynamic immune landscape associated with therapeutic response in soft tissue sarcoma C Wilding Institute of Cancer Research (University Of London), 2023 | | 2023 |
| Proteomic Features of Adolescents and Young Adults with Soft Tissue Tumours YB Tam, K Low, H PS, M Chadha, J Burns, C Wilding, A Arthur, T Chen, ... bioRxiv, 2023.11. 18.567667, 2023 | | 2023 |
| Proteomic characterisation of Sarculator nomogram-defined risk groups in soft tissue sarcomas of the extremities and trunk wall M Chadha, S Iadecola, A Jenks, J Burns, A Arthur, V Pankova, C Wilding, ... bioRxiv, 2023.11. 14.567122, 2023 | | 2023 |
| Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis. Cancers 2022, 14, 2907 L Krasny, CP Wilding, E Perkins, A Arthur, N Guljar, AD Jenks, C Fisher, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | | 2022 |
